NCT02450812View on ClinicalTrials.gov

Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany

CompletedOBSERVATIONAL
Enrollment

86

Participants

Timeline

Start Date

May 28, 2015

Primary Completion Date

June 30, 2020

Study Completion Date

September 17, 2020

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

Radium-223-dichloride (Xofigo, BAY88-8223)

according to Summary of Product Characteristics

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY